{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:27:39Z","timestamp":1786883259724,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102615","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:11:32Z","timestamp":1783923092000},"page":"102615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer by Race, Initial Diagnosis, and Family History: Results From the TRUMPET Registry"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-8303","authenticated-orcid":false,"given":"Lawrence","family":"Karsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-323X","authenticated-orcid":false,"given":"Clara","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Symanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shevrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Elsouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Spalding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-7529","authenticated-orcid":false,"given":"Pavol","family":"Kral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"El-Chaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5_suppl","key":"10.1016\/j.clgc.2026.102615_bib0001","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18","article-title":"Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102615_bib0002","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102615_bib0003","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102615_bib0004","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s12094-019-02274-w","article-title":"Age, Gleason score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (uro-oncological tumors) of the Spanish Society of Radiation Oncology (SEOR)","volume":"22","author":"Valero","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102615_bib0005","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pros.23141","article-title":"Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies","volume":"76","author":"Nadal","year":"2015","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.clgc.2026.102615_bib0006","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.clgc.2026.102615_bib0007","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases","volume":"26","author":"Schoen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.clgc.2026.102615_bib0008","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00432-018-2596-6","article-title":"Impact of comorbidities at diagnosis on prostate cancer treatment and survival","volume":"144","author":"Matthes","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2026.102615_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15204945","article-title":"De novo metastatic prostate cancer: are we moving toward a personalized treatment?","volume":"15","author":"Piombino","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.clgc.2026.102615_bib0010","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/JU.0000000000003370","article-title":"The role of physician specialty in the underutilization of standard-of-care treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"209","author":"Swami","year":"2023","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102615_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.35728","article-title":"Barriers and facilitators of treatment intensification in metastatic castration-sensitive prostate cancer","volume":"8","author":"Loeb","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.clgc.2026.102615_bib0012","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07174-9","article-title":"Survival outcomes in men with a positive family history of prostate cancer: a registry based study","volume":"20","author":"Ang","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102615_bib0013","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2022.11.019","article-title":"Family history of prostate cancer and survival outcomes in the UK genetic prostate cancer study","volume":"83","author":"Brook","year":"2023","journal-title":"Eur Urol"},{"issue":"62","key":"10.1016\/j.clgc.2026.102615_bib0014","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jncimonographs\/lgad018","article-title":"Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors","volume":"2023","author":"Gulati","year":"2023","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"23","key":"10.1016\/j.clgc.2026.102615_bib0015","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.2217\/fon-2016-0298","article-title":"Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research","volume":"12","author":"Penson","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2026.102615_bib36","unstructured":"Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.5.2026. \u00a9 2026 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines\u00ae and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"10502","key":"10.1016\/j.clgc.2026.102615_bib0016","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clgc.2026.102615_bib0017","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2026.02.009","article-title":"Final overall survival results from EORTC 1333\/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer","volume":"37","author":"Gillessen","year":"2026","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102615_bib0018","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102615_bib0019","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO-25-02693","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO Living Guideline, version 2026.1","volume":"44","author":"Taplin","year":"2026","journal-title":"J Clin Oncol"},{"issue":"10398","key":"10.1016\/j.clgc.2026.102615_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"10459","key":"10.1016\/j.clgc.2026.102615_bib0021","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.clgc.2026.102615_bib0022","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102615_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.48707","article-title":"Physician reasons for or against treatment intensification in patients with metastatic prostate cancer","volume":"7","author":"Agarwal","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.clgc.2026.102615_bib0024","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.clgc.2022.06.017","article-title":"Treatment intensification patterns and utilization in patients with metastatic castration-sensitive prostate cancer","volume":"20","author":"Heath","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102615_bib0025","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102615_bib0026","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clgc.2026.102615_bib0027","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2024.0851","article-title":"Genetic testing in men with metastatic castration-resistant prostate cancer","volume":"10","author":"Barata","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102615_bib0028","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00345-015-1738-6","article-title":"Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy","volume":"34","author":"Westerman","year":"2016","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102615_bib0029","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102615_bib0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41391-021-00463-9","article-title":"Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer","volume":"25","author":"George","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102615_bib0031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.euros.2024.01.004","article-title":"Evaluation of survival outcomes among black and white patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"61","author":"Yang","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.clgc.2026.102615_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42093","article-title":"Outcomes among African American and Non-Hispanic white men with metastatic castration-resistant prostate cancer with first-line abiraterone","volume":"5","author":"Marar","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clgc.2026.102615_bib0033","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41391-022-00622-6","article-title":"Prostate-specific antigen response and clinical progression-free survival in black and white men with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting","volume":"26","author":"Freedland","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.clgc.2026.102615_bib0034","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.urolonc.2016.12.016","article-title":"Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer","volume":"35","author":"Ramalingam","year":"2017","journal-title":"Urol Oncol"},{"issue":"5S","key":"10.1016\/j.clgc.2026.102615_bib0035","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001110200.18879.65.09","article-title":"Ip26-09 real-world treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer treated in community urology centers in the US: a cohort study using the precision (prostate cancer disease observation) data platform","volume":"213","author":"Shore","year":"2025","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:27:59Z","timestamp":1786879679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1558767326001151"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102615","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer by Race, Initial Diagnosis, and Family History: Results From the TRUMPET Registry","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102615"}}